Mirxes Holding Company Limited (HKG:2629)

Market Cap	4.50B
Revenue (ttm)	166.32M +19.3%
Net Income	-598.38M
EPS	-4.38
Shares Out	295.19M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	9,463,700
Average Volume	4,734,738
Open	16.00
Previous Close	15.21
Day's Range	14.62 - 16.30
52-Week Range	13.79 - 77.30
Beta	n/a
RSI	21.00
Earnings Date	May 15, 2026

About Mirxes Holding Company

Mirxes Holding Company Limited, a micro ribonucleic acid technology company, provides diagnostic solutions for the screening of cancer, cardiovascular, metabolic, and infectious diseases accessible across Singapore and China. The company offers GASTROClear, a blood-based miRNA detection panel consisting of 12 miRNA biomarkers for gastric cancer screening; LUNGClear, a lung cancer screening product candidate; and Fortitude COVID-19 RT-qPCR test kits. It also researches, develops, and manufactures biotechnology, life, and medical science related ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Employees: 347
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2629

Financial Performance

In 2024, Mirxes Holding Company's revenue was $20.28 million, a decrease of -16.14% compared to the previous year's $24.19 million. Losses were -$92.33 million, 33.4% more than in 2023.

Financial numbers in USD